Cell Signaling & Oncology

Axon Ligands™ for Cell Signaling & Oncology Research

The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].

Cell Signaling and Oncology products Library

For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.

Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.

Axon Ligands™ for Epigenetic research   Axon 5051 - Cell signaling and Oncology Library.xls                   

 

[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.

21 Item(s)

per page
Axon ID Name Description From price
2231 XL 019 JAK2 inhibitor €100.00
2316 WP 1066 Potent JAK2 and STAT3 inhibitor and downregulator of antiapoptotic proteins €95.00
2072 Tofacitinib citrate Potent Janus Kinase 3 (JAK3) inhibitor €115.00
1588 TG 101348 JAK2 inhibitor €80.00
2539 Solcitinib Selective JAK1 inhibitor for treatment of degenerative and inflammatory diseases €90.00
1598 Ruxolitinib JAK1 and JAK2 inhibitor €65.00
2217 PF 956980 JAK3 inhibitor; analogue of Axon 1338 and 2072 €90.00
2792 NVP-BSK805 Potent, selective and orally bioavailable JAK2 inhibitor €125.00
4124 Momelotinib hydrochloride JAK1 and JAK2 inhibitor €120.00
1681 Momelotinib JAK1 and JAK2 inhibitor €80.00
2554 LY 2784544 Potent, selective and ATP-competitive inhibitor of mutated janus kinase 2 (JAK2V617F) €95.00
1843 JAK2 inhibitor 13 JAK2 inhibitor €110.00
4006 GLPG-0634 The first orally-available, selective inhibitor of JAK1 Inquire
3861 Decernotinib Potent and selective,orally bioavailable Janus kinase 3 (JAK3) inhibitor Inquire
1338 CP 690550 JAK3 inhibitor €60.00
3671 CEP-33779 Potent, selective and orally bioavailable JAK2 inhibitor €95.00
3813 BMS-911543 Potent, selective and orally active inhibitor of JAK2 Inquire
1955 Baricitinib Inhibitor of JAK1 and JAK2 €70.00
3855 AZD-4205 Selective and ATP-competitive inhibitor of JAK1 Inquire
1778 AZ 960 JAK2 inhibitor €95.00
1378 AG 490 JAK2 inhibitor €65.00

21 Item(s)

per page
Please wait...